Tags : Sumitomo Dainippon

Weekly Snapshot

PharmaShots Weekly Snapshot (September 09 – 13, 2019)

1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, E2609, Early Alzheimer’s Disease 2. GE Healthcare’s Critical Care Suite AI-Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax Published: Sept 12, 2019 | Tags: […]Read More

Pharma

Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III

Shots:  The P-III JEWEL Study involves assessing lurasidone (40 mg/day) vs PBO @6wks. in 483 patients with Schizophrenia, conducted for regulatory approval in Japan The P-III JEWEL Study results demonstrated the patients treated with Lurasidone responded positively; PANSS (Positive and Negative Syndrome Scale) score (-19.3 vs -12.7); AE (47.0% vs 51.1%); patients discontinued treatment (19.4% […]Read More